A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability
VeraCept Phase III
Sponsor: Sebela Pharmaceuticals Development LLC
Enrolling: Female Patients Only
Clinic Visits: 14
IRB Number: AAAS0078
Contact: Connie Colon: 212-305-6098 / cc3238@cumc.columbia.edu
Additional Study Information: We are asking you to participate in this research study because you are a woman of child-bearing age or potential and interested in using an intrauterine device (IUD) for birth control for up to 5 years.
This study is closed
Investigator
Paula Castano, MD, MPH
Do You Qualify?
Have you had previous IUD complications such as expulsion, infection, etc.? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Connie Colon
cc3238@cumc.columbia.edu
212-305-6098
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE